BACKGROUND: An emerging endophenotype of schizophrenia is the reduction of both power and phase locking of the 40 Hz auditory steady state response (ASSR), and there have been a number of reports linking increased γ activity with positive psychotic symptoms. Schizophrenia and, more specifically, positive psychotic symptoms have been closely linked to increased dopamine (DA) neurophysiology. Therefore, we gave dexamphetamine to healthy participants to determine the effect that increased DA transmission would have on the ASSR. METHODS: We administered 0.45 mg/kg of dexamphetamine orally in a double-blind placebo-controlled crossover study. Stimuli were 20 Hz and 40 Hz click trains presented in an auditory oddball-type stimulus format (probability of stimulus presentation: 0.2 for targets, 0.8 for nontargets). RESULTS: We included 44 healthy volunteers (18 women) in the study. Dexamphetamine significantly increased the 40 Hz power for both target and nontarget ASSR stimuli. Dexamphetamine did not significantly affect the 40 Hz phase-locking factor (PLF) or the 20 Hz power and PLF. Whereas there were significant effects of selective attention on power and PLF for 20 and 40 Hz ASSR, there were no significant interactions between dexamphetamine and selective attention. LIMITATIONS: Dexamphetamine releases both noradrenaline and DA with equal potency. Further research with selective dopaminergic and noradrenergic agents will better characterize the effects of monoamines on γ activity. CONCLUSION: The results demonstrate a frequency-specific effect of dexamphetamine on the ASSR. This finding is consistent with previous research that has found an association between increased γ and positive symptoms of psychosis. However, this result also raises the possibility that previous 40 Hz ASSR findings in people with schizophrenia may be confounded by effects of antipsychotic medication. Possible neural mechanisms by which dexamphetamine specifically increases 40 Hz power are also discussed. AUSTRALIAN AND NEW ZEALAND CLINICAL TRIALS REGISTRY NUMBER: ACTRN12608000610336.
RCT Entities:
BACKGROUND: An emerging endophenotype of schizophrenia is the reduction of both power and phase locking of the 40 Hz auditory steady state response (ASSR), and there have been a number of reports linking increased γ activity with positive psychotic symptoms. Schizophrenia and, more specifically, positive psychotic symptoms have been closely linked to increased dopamine (DA) neurophysiology. Therefore, we gave dexamphetamine to healthy participants to determine the effect that increased DA transmission would have on the ASSR. METHODS: We administered 0.45 mg/kg of dexamphetamine orally in a double-blind placebo-controlled crossover study. Stimuli were 20 Hz and 40 Hz click trains presented in an auditory oddball-type stimulus format (probability of stimulus presentation: 0.2 for targets, 0.8 for nontargets). RESULTS: We included 44 healthy volunteers (18 women) in the study. Dexamphetamine significantly increased the 40 Hz power for both target and nontarget ASSR stimuli. Dexamphetamine did not significantly affect the 40 Hz phase-locking factor (PLF) or the 20 Hz power and PLF. Whereas there were significant effects of selective attention on power and PLF for 20 and 40 Hz ASSR, there were no significant interactions between dexamphetamine and selective attention. LIMITATIONS: Dexamphetamine releases both noradrenaline and DA with equal potency. Further research with selective dopaminergic and noradrenergic agents will better characterize the effects of monoamines on γ activity. CONCLUSION: The results demonstrate a frequency-specific effect of dexamphetamine on the ASSR. This finding is consistent with previous research that has found an association between increased γ and positive symptoms of psychosis. However, this result also raises the possibility that previous 40 Hz ASSR findings in people with schizophrenia may be confounded by effects of antipsychotic medication. Possible neural mechanisms by which dexamphetamine specifically increases 40 Hz power are also discussed. AUSTRALIAN AND NEW ZEALAND CLINICAL TRIALS REGISTRY NUMBER: ACTRN12608000610336.
Authors: Kevin M Spencer; Paul G Nestor; Ruth Perlmutter; Margaret A Niznikiewicz; Meredith C Klump; Melissa Frumin; Martha E Shenton; Robert W McCarley Journal: Proc Natl Acad Sci U S A Date: 2004-11-16 Impact factor: 11.205
Authors: Gregory A Light; Jung Lung Hsu; Ming H Hsieh; Katrin Meyer-Gomes; Joyce Sprock; Neal R Swerdlow; David L Braff Journal: Biol Psychiatry Date: 2006-08-07 Impact factor: 13.382
Authors: Axel Ropohl; Wolfgang Sperling; Samuel Elstner; Bernd Tomandl; Udo Reulbach; Martin Kaltenhäuser; Johannes Kornhuber; Christian Maihöfner Journal: Neuroreport Date: 2004-03-01 Impact factor: 1.837
Authors: Vojtěch Viktorin; Inga Griškova-Bulanova; Aleksandras Voicikas; Dominika Dojčánová; Peter Zach; Anna Bravermanová; Veronika Andrashko; Filip Tylš; Jakub Korčák; Michaela Viktorinová; Vlastimil Koudelka; Kateřina Hájková; Martin Kuchař; Jiří Horáček; Martin Brunovský; Tomáš Páleníček Journal: J Pers Med Date: 2022-06-19
Authors: Matthew A Albrecht; Gareth Roberts; Greg Price; Joseph Lee; Rajan Iyyalol; Mathew T Martin-Iverson Journal: Hum Brain Mapp Date: 2015-11-18 Impact factor: 5.038
Authors: Rick A Adams; Dimitris Pinotsis; Konstantinos Tsirlis; Leonhardt Unruh; Aashna Mahajan; Ana Montero Horas; Laura Convertino; Ann Summerfelt; Hemalatha Sampath; Xiaoming Michael Du; Peter Kochunov; Jie Lisa Ji; Grega Repovs; John D Murray; Karl J Friston; L Elliot Hong; Alan Anticevic Journal: Biol Psychiatry Date: 2021-08-10 Impact factor: 13.382